New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

The United States and the United Kingdom announced a high-level trade deal Monday that would exempt U.K. pharmaceuticals from ...

Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...

Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Explore the shift towards localization and innovation in the Middle East's pharmaceutical industry, with insights from experts about market growth, regulatory challenges, and the role of technology in ...

IonQ , the world's leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic ...

There's been a lot of talk about using artificial intelligence in drug development over the past year. Now, it’s a lot closer ...

The global targeted drugs for allergic diseases market size was valued at USD 13.96 billion in 2024 and is predicted to hit ...

The Global Alzheimer’s Therapeutics Market Growth is Driven by the Rising Prevalence of Alzheimer’s Disease and the Expanding Adoption of Disease Modifying Therapies.Austin, Dec. 01, 2025 (GLOBE ...